达格列净治疗糖尿病肾病患者的临床研究

Clinical Study of Dapagliflozin in the Treatment of Diabetic Nephropathy

目的探讨对糖尿病肾病患者实施达格列净治疗的临床效果。方法在2019年11月—2020年11月期间选取60例糖尿病肾病患者,将其按照随机数字表法分组,每组30例。对照组实施常规降糖药物治疗,研究组基于对照组治疗方案实施达格列净治疗,对比分析两组临床效果。结果治疗后研究组空腹血糖、餐后2 h血糖、糖化血红蛋白水平均低于对照组,差异有统计学意义(P<0.05);治疗后研究组24 h尿微量白蛋白低于对照组,24 h尿糖高于对照组,差异有统计学意义(P<0.05);治疗后研究组肿瘤坏死因子-α、白介素-1β均低于对照组,差异有统计学意义(P<0.05);两组低血糖、尿路感染、恶心呕吐等不良反应总发生率对比差异无统计学意义(P>0.05)。结论对于糖尿病肾病患者来说,达格列净治疗可有效改善血糖,使肾功能得到保护,还可以减轻炎症,具备较高的安全性,临床价值显著。

Objective To explore the clinical effect of dapagliflozin treatment in patients with diabetic nephropathy.Methods From November 2019 to November 2020,60 patients with diabetic nephropathy were selected and grouped according to the random number table method,with 30 cases in each group.The control group was treated with conventional hypoglycemic drugs,and the study group was treated with dapagliflozin based on the treatment plan of the control group.The clinical effects of the two groups were compared and analyzed.Results After treatment,the fasting blood glucose,2 h postprandial blood glucose,and glycosylated hemoglobin level of the study group were lower than those of the control group,the difference was statistically significant(P<0.05);24 h urine microalbumin in the study group was lower than the control group after treatment.24 h urine glucose was higher than the control group,the difference was statistically significant(P<0.05);after treatment,tumor necrosis factor-αand interleukin-1βin the study group were lower than the control group,the difference was statistically significant(P<0.05);There was no significant difference in the total incidence of adverse reactions such as hypoglycemia,urinary tract infection,nausea and vomiting between the two groups(P>0.05).Conclusion For patients with diabetic nephropathy,dapagliflozin treatment can effectively improve blood sugar,protect renal function,and reduce inflammation.It has high safety and significant clinical value.